Xlife Sciences AG (XSWX:XLS) Change In Receivables: CHF8.37 Mil (TTM As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.15
GF Value CHF7.25
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Change In Receivables?

Xlife Sciences AG XSWX:XLS 53 Change In Receivables is CHF8.37 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.25 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's change in receivables for the quarter that ended in Dec. 2025 was CHF9.32 Mil. It means Xlife Sciences AG's Accounts Receivable declined by CHF9.32 Mil from Jun. 2025 to Dec. 2025 .

Xlife Sciences AG's change in receivables for the fiscal year that ended in Dec. 2025 was CHF8.37 Mil. It means Xlife Sciences AG's Accounts Receivable declined by CHF8.37 Mil from Dec. 2024 to Dec. 2025 .

Xlife Sciences AG's Accounts Receivable for the quarter that ended in Dec. 2025 was CHF0.09 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Xlife Sciences AG's liquidation value for the six months ended in Dec. 2025 was CHF-143.62 Mil.

Xlife Sciences AG  (XSWX:XLS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Xlife Sciences AG's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.094/-0.079*91
=

2. In Ben Graham's calculation of liquidation value, Xlife Sciences AG's accounts receivable are only considered to be worth 75% of book value:

Xlife Sciences AG's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1.051-144.758+0.75 * 0.094+0.5 * 0.029
=-143.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Change In Receivables Related Terms

Xlife Sciences AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Change In Receivables Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -0.20 -0.26 -8.58 -0.00 8.37

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.38 -0.03 0.03 -0.95 9.32
XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF8.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of CHF8.37 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Change In Receivables of CHF8.37 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Change In Receivables too high?
Xlife Sciences AG's current Change In Receivables is CHF8.37 Mil. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Change In Receivables compare to VRTX and REGN?
Xlife Sciences AG's Change In Receivables of CHF8.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current Change In Receivables is CHF8.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.25, compared to a current price of CHF18.15 — trading 150.3% above its estimated fair value. The current Change In Receivables is CHF8.37 Mil. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Change In Receivables is CHF8.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.15 is trading 150.3% above its estimated GF Value™ of CHF7.25. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Change In Receivables: CHF8.37 Mil
  • GF Value™: CHF7.25 vs. price of CHF18.15 (150.3% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.15
Price
CHF7.25
GF Value